Skip to main content Skip to section navigation Skip to footer

NeonMind Biosciences Inc.

  • Home
  • About
    • Overview
    • R&D Advisory Board
    • Specialty Clinics Advisory Board
    • Management Team
    • Board of Directors
  • Our Science
  • Divisions
    • Overview
    • Pharmaceutical
    • Medical Services
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Stock Data
    • SEDAR
    • Governance
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events
Jun 14, 2021 6:00am EDT

NeonMind to Present at H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference

Jun 10, 2021 6:00am EDT

NeonMind Announces Vitasave Will Carry NeonMind Functional Mushroom Products

May 26, 2021 6:00am EDT

NeonMind Announces Creation of Medical Clinics Advisory Board to Guide Planning and Operation of Company-Branded Clinics Across Canada

May 10, 2021 6:00am EDT

NeonMind to Present at the Benzinga Global Small Cap Conference

Apr 22, 2021 6:00am EDT

NeonMind Announces New Specialty Clinics Division to Deliver Innovative Mental Health Services, Appoints New VP, Corporate Development

Apr 06, 2021 6:00am EDT

NeonMind Developing Music Playlist for Psychedelic Therapy Sessions

Mar 30, 2021 6:00am EDT

NeonMind CEO Robert Tessarolo to Speak at the Psychedelic, Therapeutics, & Drug Development Conference

Mar 23, 2021 2:00am EDT

NeonMind CEO Provides Update on the Progress of its Psilocybin Drug Development Research Plan and Team

Mar 11, 2021 6:00am EST

NeonMind Engages Certara to Advance its Synthetic Psilocybin Drug Candidates for Obesity

Mar 09, 2021 2:00am EST

NeonMind Engages Pharma Executive Philippe Martin to Advance its Psilocybin Drug Candidates for Obesity

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • arrow_forward
rss_feed News RSS
©2022 NeonMind Biosciences Inc. All Rights Reserved.
Facebook LinkedIn Instagram
Privacy Policy Disclaimer Sitemap